☆ 4.7 Article

Post-protocol therapy and informative censoring in the CANDOR study

LANCET ONCOLOGY (2022)

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

Saad Z. Usmani et al.

Summary: This study compares the efficacy and safety of carfilzomib, daratumumab, and dexamethasone (KdD) with carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma. The results demonstrate a clear and sustained progression-free survival benefit with KdD over Kd, indicating that KdD is emerging as the standard of care for these patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review

Ghulam Rehman Mohyuddin et al.

Lancet Haematology (2021)

添加到收藏夹

Article Oncology

Informative censoring of surrogate end-point data in phase 3 oncology trials

Shai Gilboa et al.

Summary: This study analyzed the patterns of censoring in surrogate endpoints in oncology RCTs between 2010 and 2020. Results showed that censoring imbalance between study arms could potentially affect the validity of the results, especially in trials where new treatments failed to demonstrate survival benefit.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology